Trevena, Inc. (Trevena) is a clinical stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, it has identified and advanced two differentiated product candidates into the clinic. It has completed a Phase 2a clinical trial and plan to initiate a Phase IIb clinical trial of TRV027 for acute heart failure (AHF). The Company's other lead program, TRV130, has completed a Phase Ib clinical trial to evaluate its potential to treat moderate to severe acute pain intravenously. The Company�s pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand.